Enclomiphene Citrate vs AndroGel: Switching Between Them

How Each Drug Works

Enclomiphene citrate and AndroGel correct low testosterone through opposite mechanisms, and that difference shapes every clinical decision around switching.

Enclomiphene is the trans-isomer of clomiphene citrate. It blocks estrogen receptors in the hypothalamus, which removes negative feedback on gonadotropin-releasing hormone (GnRH). The pituitary responds by increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. LH drives Leydig cells to produce more testosterone; FSH supports Sertoli cell function and spermatogenesis. In a study by Kim et al. published in BJU International (2016), enclomiphene restored serum testosterone into the normal range while preserving sperm parameters in men with secondary hypogonadism 1.

AndroGel, by contrast, is a hydroalcoholic gel delivering pharmaceutical-grade testosterone through the skin. It bypasses the hypothalamic-pituitary-gonadal (HPG) axis entirely. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum T below 275 ng/dL, confirmed that daily topical testosterone raised levels into the normal range and improved sexual function, physical activity, and mood over 12 months 2. The tradeoff: exogenous testosterone suppresses GnRH, LH, and FSH through negative feedback, which reduces or halts sperm production in most men within 3 to 6 months of continuous use.

That core divergence, stimulating the axis versus replacing it, determines who benefits from which drug and how safely a patient can transition.

Testosterone Efficacy: Head-to-Head Reality

No large randomized controlled trial has directly compared enclomiphene citrate against AndroGel in the same patient population. Clinicians rely on indirect evidence from separate trials.

Kim et al. reported that enclomiphene 25 mg daily raised mean serum testosterone from a hypogonadal baseline to approximately 450 to 500 ng/dL over 12 to 24 weeks, with concurrent increases in LH and FSH 1. The TTrials showed that testosterone gel (applied at doses titrated to achieve trough levels of 400 to 500 ng/dL) produced improvements across sexual function, vitality, and bone mineral density endpoints over one year 2.

Both drugs reach similar target ranges. The difference is ceiling. Men whose Leydig cell reserve is severely compromised (primary hypogonadism with elevated LH at baseline) may not respond adequately to enclomiphene because the drug depends on functional testicular tissue. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends exogenous testosterone for confirmed male hypogonadism and notes that SERMs like clomiphene are used off-label, particularly when fertility preservation is a goal 3.

Dr. Shalender Bhasin, lead author of the Endocrine Society guideline, stated: "The decision to use testosterone therapy should be individualized, weighing the potential benefits against the risks, and taking into account the patient's preferences and fertility plans" 3.

For men with secondary hypogonadism (low T with low or inappropriately normal LH/FSH), enclomiphene can match exogenous gel in restoring physiologic testosterone. For men with primary testicular failure, AndroGel is the more reliable choice.

Fertility: The Decisive Factor

This is often the reason a switch happens in the first place.

AndroGel suppresses the HPG axis. Within 3 to 6 months of daily use, most men see sperm concentrations drop below 1 million/mL, and some reach azoospermia. A study published in the Journal of Clinical Endocrinology & Metabolism found that exogenous testosterone administration led to azoospermia or severe oligospermia in approximately 65% of men within 6 months 4. Recovery after discontinuation varies: most men recover baseline sperm counts within 6 to 18 months, but a subset (estimated at 5 to 10%) may have prolonged or incomplete recovery.

Enclomiphene preserves fertility by design. Because it works through the pituitary, FSH secretion continues, Sertoli cells remain supported, and spermatogenesis stays intact. Kim et al. confirmed that sperm concentration and motility were maintained in the enclomiphene arm 1.

A 32-year-old man on AndroGel who wants to start a family in the next 12 to 24 months faces a real clinical problem. Stopping the gel and waiting for HPG axis recovery can leave him hypogonadal and subfertile for months. Switching to enclomiphene can bridge that gap: it maintains testosterone levels while actively supporting gonadotropin-driven spermatogenesis.

The American Urological Association (AUA) notes that exogenous testosterone should not be prescribed to men desiring fertility, and that alternatives like clomiphene citrate or human chorionic gonadotropin (hCG) should be considered 5.

Switching from AndroGel to Enclomiphene

Moving off exogenous testosterone and onto a SERM requires patience. The HPG axis does not reactivate overnight.

After stopping AndroGel, serum testosterone will drop as the exogenous supply clears (the gel's half-life means testosterone levels fall meaningfully within 24 to 72 hours of the last application). LH and FSH, which have been suppressed by negative feedback, take longer to recover. Most men see gonadotropin levels begin rising within 2 to 4 weeks, but full recovery to pre-suppression levels can take 1 to 3 months or longer depending on duration of prior use.

Starting enclomiphene during this transition shortens the symptomatic window. The SERM provides immediate hypothalamic estrogen blockade, prompting LH and FSH release even while the axis is still recovering. A practical protocol used by many TRT clinicians involves the following steps.

Stop AndroGel application. Begin enclomiphene 25 mg daily the following morning. Check total testosterone, free testosterone, LH, FSH, and estradiol at 4 weeks. Adjust enclomiphene dose at 6 to 8 weeks based on lab results. If fertility is a concern, obtain a semen analysis at 3 months.

Some men experience a temporary dip in testosterone during weeks 1 to 3 as the exogenous gel washes out and the pituitary has not yet fully responded to enclomiphene's stimulus. Symptoms like fatigue, reduced libido, or mood changes during this period are expected and typically self-limiting.

Men who used AndroGel for more than 2 years may have more sluggish axis recovery. In such cases, the addition of low-dose hCG (500 to 1,000 IU subcutaneously two to three times per week) during the first 4 to 6 weeks of transition can help "jump-start" Leydig cell function while enclomiphene works on the pituitary 6.

Switching from Enclomiphene to AndroGel

This direction is simpler. Straightforward, even.

Because enclomiphene does not suppress the HPG axis, there is no recovery period needed. A man can stop enclomiphene and apply his first dose of AndroGel the next day. Serum testosterone will initially fluctuate as endogenous production tapers (enclomiphene's effects on LH/FSH diminish over 5 to 7 days) and the gel's transdermal delivery ramps up.

The standard starting dose of AndroGel 1% is 50 mg (one 5 g packet or four pump actuations) applied to the shoulders and upper arms daily. The Endocrine Society guideline recommends checking serum T levels 2 to 4 weeks after initiation, drawn 2 to 8 hours post-application, and titrating to a target of 450 to 600 ng/dL 3.

Why would someone switch in this direction? Common reasons include inadequate testosterone response on enclomiphene (particularly in men with partial primary hypogonadism), persistent symptoms despite normal lab values, or a change in fertility goals. A man who has completed his family may prefer the simplicity and reliability of direct testosterone replacement.

The key counseling point: once AndroGel suppresses the HPG axis (typically within 4 to 8 weeks), spermatogenesis will decline. This switch should be treated as a fertility decision, not just a hormone decision.

Side Effect Profiles

Each drug carries distinct risks shaped by its mechanism.

Enclomiphene's side effects stem from its estrogen-modulating activity. The most commonly reported effects include visual disturbances (blurring, floaters), headache, and mood changes. Elevated estradiol can occur because increased LH-driven testosterone production leads to more aromatization. In Kim et al., the adverse event profile was mild, with no serious events attributed to enclomiphene 1. Long-term safety data beyond 2 to 3 years remain limited because the drug has not completed the FDA approval process for hypogonadism.

AndroGel carries the risks common to all exogenous testosterone formulations. The FDA mandated a black box warning in 2015 regarding the risk of secondary exposure (transfer to women and children through skin contact). Erythrocytosis is the most common laboratory abnormality, occurring in roughly 5 to 15% of men on topical T, requiring hematocrit monitoring every 6 to 12 months. The TTrials found a higher incidence of cardiovascular events in the testosterone arm versus placebo in men with pre-existing coronary disease, though the overall numbers were small and the study was not powered for cardiovascular endpoints 2.

Dr. Alvin Matsumoto, a principal investigator in the TTrials, noted: "Testosterone treatment increased coronary artery noncalcified plaque volume, a finding that warrants further investigation regarding cardiovascular safety" 7.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided the largest randomized dataset on cardiovascular safety of testosterone replacement. It found that testosterone gel was noninferior to placebo for major adverse cardiovascular events (MACE) in men aged 45 to 80 with cardiovascular risk factors. The hazard ratio for MACE was 0.96 (95% CI, 0.78 to 1.17), which did not meet criteria for increased cardiovascular harm 8.

Cost and Access Considerations

AndroGel is FDA-approved and widely covered by insurance formularies, though brand-name pricing can exceed $500/month without coverage. Generic testosterone gel 1% is available for $30 to $80/month through most pharmacies. Copay assistance programs from AbbVie (the AndroGel manufacturer) can reduce out-of-pocket costs for eligible patients.

Enclomiphene citrate occupies a different position. It is not FDA-approved for hypogonadism, and the branded version has not reached market as of early 2026. Compounding pharmacies produce enclomiphene capsules, typically at $40 to $100/month depending on the pharmacy and dose. Insurance coverage for compounded enclomiphene is uncommon, meaning most patients pay out of pocket. Some clinicians prescribe clomiphene citrate (which contains both the enclomiphene and zuclomiphene isomers) as an FDA-approved alternative, though zuclomiphene's longer half-life and estrogenic activity can produce more side effects 9.

Access patterns may shift if enclomiphene receives FDA approval for male hypogonadism, but for now, practical availability depends heavily on a patient's relationship with a knowledgeable prescriber and a reliable compounding pharmacy.

Who Should Choose Which

The choice between enclomiphene and AndroGel is not a question of which drug is "better" in the abstract. It depends on three clinical variables.

Fertility status. Any man who wants to preserve the option of fathering children should use enclomiphene or another SERM/hCG protocol rather than AndroGel. The AUA is clear on this point 5.

Type of hypogonadism. Secondary hypogonadism (hypothalamic or pituitary origin) responds well to enclomiphene because the testes retain the capacity to produce testosterone when stimulated. Primary hypogonadism (testicular failure, often marked by elevated LH) responds poorly to SERMs and requires exogenous replacement.

Symptom severity and treatment goals. Men with severely symptomatic hypogonadism (T levels below 200 ng/dL with significant fatigue, sexual dysfunction, and mood disturbance) often achieve faster, more predictable symptom relief with AndroGel because dosing can be titrated directly. Enclomiphene's response depends on the patient's own Leydig cell capacity and can take 4 to 8 weeks to reach steady-state testosterone levels.

Monitoring After Any Switch

Lab work is non-negotiable during transitions.

At minimum, check total testosterone, free testosterone (calculated or by equilibrium dialysis), LH, FSH, estradiol, hematocrit, and PSA at baseline and at 4, 8, and 12 weeks after switching. If switching from AndroGel to enclomiphene and fertility is a goal, add semen analysis at 3 and 6 months post-switch. The Endocrine Society recommends hematocrit monitoring every 6 to 12 months on exogenous testosterone, with dose reduction or phlebotomy if hematocrit exceeds 54% 3.

Estradiol deserves special attention in both directions. On enclomiphene, increased testosterone production leads to proportionally increased aromatization, and estradiol can climb above the reference range (typically <40 pg/mL in men). On AndroGel, the same aromatization occurs, and some men require an aromatase inhibitor if estradiol-related symptoms (gynecomastia, water retention, mood lability) develop.

The TRAVERSE trial reinforced that prostate safety monitoring (PSA and digital rectal exam) should continue on exogenous testosterone, as the trial observed a higher incidence of prostate biopsy in the testosterone arm compared to placebo 8.

Men switching between these drugs should not adjust doses independently. A 4-week recheck with their prescriber allows data-driven titration rather than symptom-chasing, which often leads to supraphysiologic dosing and avoidable side effects.